Status:

WITHDRAWN

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

Lead Sponsor:

Wake Forest University Health Sciences

Collaborating Sponsors:

Modulight

Conditions:

Exudative Age Related Macular Degeneration

Eligibility:

All Genders

50-90 years

Phase:

PHASE4

Brief Summary

Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus Standard of Care Anti-VEGF Monothe...

Detailed Description

This study is a 48 week, single center, randomized controlled clinical trial. Approximately 150 subjects will be randomized into three separate arms. This study compares the efficacy of standard of ca...

Eligibility Criteria

Inclusion

  • Willing to give written informed consent
  • Willing and able to comply with all study procedures for the duration of the study.
  • Presence of Exudative ARMD with evidence of choroidal neovascularization: type 1, 2, and/or 3 on spectral domain OCT, fluorescein angiography, indocyanine green angiogram and optical coherent tomography angiography
  • Visual Acuity of 20/25 to 20/400 at screening and baseline visits using an autorefractor or Early Treatment Diabetic Retinopathy Study
  • Intraocular pressure less than or equal to 25mmHG
  • Females of childbearing potential that are willing to use medically acceptable methods of birth control.

Exclusion

  • Exudation maculopathies without drusen
  • Previous treatment with macular photocoagulation, anti-VEGF medication or PDT with Visudyne
  • Myocardial infarction or cerebrovascular accident within the last 6 weeks
  • Previous vitrectomy
  • Optic neuropathy
  • Diabetic retinopathy
  • Traction maculopathies
  • Allergies to fluorescein and indocyanine, dilating agents or anti-VEGF medications
  • Have received previous treatment for ARMD
  • Any uncontrolled condition or illness that in the opinion of the investigator makes the subject unsuitable for the study

Key Trial Info

Start Date :

March 30 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2024

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04075136

Start Date

March 30 2023

End Date

December 1 2024

Last Update

March 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wake Forest Health Sciences

Winston-Salem, North Carolina, United States, 27157

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy | DecenTrialz